Evidence map›Paper›PMID 41419710›Full record

ReviewCurrent topics in behavioral neurosciences2026

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Ricarda Evens, Abdo Uyar, Tomislav Majić

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ricarda EvensDepartment of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany. ricarda.evens@hu-berlin.de.
Abdo UyarDepartment of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.
Tomislav MajićDepartment of Psychiatry und Neurosciences, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The subacute period following the use of classic psychedelics is often marked by an "afterglow" - a state characterized by elevated mood; enhanced psychological well-being; increased emotional openness toward self, others, and nature; and sometimes a heightened sense of clarity and existential meaning. From a neurobiological perspective, subacute psychedelic states have been associated with changes in brain network connectivity, amygdala reactivity, and neuroplasticity.However, individual responses to psychedelics vary considerably, and not all users experience positive aftereffects. Some struggle to make sense of their psychedelic experiences or to integrate them into daily life. Others report psychological instability, including mood swings, anxiety, panic attacks, sleep disturbances, depressive symptoms, feelings of alienation, depersonalization, derealization, persisting perceptual changes, flashbacks, prolonged psychosis, mania, or suicidal ideation.Many of these issues can be mitigated through interventions commonly referred to as "psychedelic integration," often practiced individually or provided by peers within the psychedelic community or through other forms of social support. In cases of severe or persistent symptoms, however, professional mental health care may be required. Key components in managing subacute complications include establishing safety, mobilizing internal and external resources, supporting the psychological processing of the experience, addressing maladaptive interpretations, monitoring symptom progression, and, when indicated, pharmacotherapy. Persistent complications may furthermore warrant established disorder-specific treatment to prevent further chronification.This chapter outlines and discusses strategies for managing clinically significant subacute complications, with the aim of advancing a nuanced harm-reduction framework relevant to research, clinical, and non-clinical contexts.

Indexed as

HallucinogensMental DisordersHumansHallucinogensAfterglowChallengingIntegrationPsychedelicSubacute

Identifiers

PMID41419710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.